Avalo Therapeutics, Inc.AVTXEarnings & Financial Report
Nasdaq
NextMar 31, 2026
AVTX Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-19.2M
Net Profit
$-30.6M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-2.19
Avalo Therapeutics, Inc. Q3 2025 Financial Summary
Avalo Therapeutics, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-30.6M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-30.6M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
Avalo Therapeutics, Inc. Annual Revenue by Year
Avalo Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $441.0K).
| Year | Annual Revenue |
|---|---|
| 2024 | $441.0K |
| 2023 | $1.9M |
| 2022 | $18.1M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $570000 | $0 | $0 | $249000 | $192000 | $0 | $0 | $0 |
| YoY Growth | -36.4% | N/A | N/A | 5.5% | -66.3% | N/A | N/A | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $21.0M | $123.7M | $108.3M | $98.5M | $150.7M | $138.5M | $126.6M | $125.1M |
| Liabilities | $13.7M | $224.8M | $110.5M | $75.7M | $17.7M | $15.9M | $22.0M | $33.6M |
| Equity | $7.3M | $-112.5M | $-13.6M | $21.1M | $133.0M | $122.6M | $104.6M | $91.5M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.8M | $-6.2M | $-16.3M | $-11.5M | $-15.0M | $-9.5M | $-11.4M | $-16.4M |